Liquidia Corporation (LQDA)
Largest Insider Buys in Sector
LQDA Stock Price History Chart
LQDA Stock Performance
About Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Insider Activity of Liquidia Corporation
Over the last 12 months, insiders at Liquidia Corporation have bought $15.43M and sold $3.5M worth of Liquidia Corporation stock.
On average, over the past 5 years, insiders at Liquidia Corporation have bought $12.31M and sold $10.24M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Manning Paul B (director) — $25M. Caligan Partners LP () — $9.43M. JEFFS ROGER (Chief Executive Officer) — $4M.
The last purchase of 337,078 shares for transaction amount of $3M was made by Manning Paul B (director) on 2024‑09‑12.
List of Insider Buy and Sell Transactions, Liquidia Corporation
| 2024-10-28 | Sale | Chief Business Officer | 459 0.0006% | $11.31 | $5,190 | -2.37% | ||
| 2024-10-18 | Sale | Chief Medical Officer | 2,526 0.003% | $11.19 | $28,266 | -1.30% | ||
| 2024-10-14 | Sale | Chief Executive Officer | 8,053 0.0106% | $11.11 | $89,450 | -0.67% | ||
| 2024-10-14 | Sale | General Counsel | 2,576 0.0034% | $11.11 | $28,613 | -0.67% | ||
| 2024-10-14 | Sale | CFO and COO | 3,892 0.0051% | $11.11 | $43,231 | -0.67% | ||
| 2024-10-14 | Sale | Chief Medical Officer | 2,260 0.003% | $11.11 | $25,103 | -0.67% | ||
| 2024-10-14 | Sale | Chief Commercial Officer | 1,527 0.002% | $11.11 | $16,961 | -0.67% | ||
| 2024-10-14 | Sale | Chief Business Officer | 1,146 0.0015% | $11.11 | $12,729 | -0.67% | ||
| 2024-09-12 | director | 337,078 0.4019% | $8.90 | $3M | +11.63% | |||
| 2024-09-03 | Sale | General Counsel | 710 0.001% | $9.50 | $6,745 | +12.31% | ||
| 2024-09-03 | Sale | CFO and COO | 1,079 0.0015% | $9.50 | $10,250 | +12.31% | ||
| 2024-09-03 | Sale | Chief Commercial Officer | 546 0.0007% | $9.50 | $5,187 | +12.31% | ||
| 2024-09-03 | Sale | Chief Business Officer | 455 0.0006% | $9.50 | $4,322 | +12.31% | ||
| 2024-08-30 | Sale | See Remarks | 150,000 0.1953% | $9.51 | $1.43M | +6.78% | ||
| 2024-08-30 | See Remarks | 150,000 0.1953% | $9.51 | $1.43M | +6.78% | |||
| 2024-07-26 | Sale | Chief Business Officer | 1,833 0.0024% | $11.44 | $20,970 | -13.24% | ||
| 2024-07-19 | Sale | Chief Medical Officer | 1,873 0.0025% | $11.13 | $20,846 | -7.54% | ||
| 2024-07-12 | Sale | Chief Executive Officer | 8,053 0.0107% | $12.53 | $100,904 | 0.00% | ||
| 2024-07-12 | Sale | General Counsel | 1,985 0.0026% | $12.53 | $24,872 | 0.00% | ||
| 2024-07-12 | Sale | CFO and COO | 3,906 0.0052% | $12.53 | $48,942 | 0.00% |
Insider Historical Profitability
| Caligan Partners LP | See Remarks | 6994997 8.402% | $10.50 | 2 | 1 | |
| Manning Paul B | director | 816311 0.9805% | $10.50 | 4 | 0 | +16.39% |
| JEFFS ROGER | Chief Executive Officer | 812193 0.9756% | $10.50 | 5 | 4 | +34.86% |
| Schundler Russell | General Counsel | 486048 0.5838% | $10.50 | 2 | 6 | +38.84% |
| Kaseta Michael | CFO and COO | 311076 0.3736% | $10.50 | 2 | 6 | +33.43% |
Institutional Investor Ownership
| Caligan Partners LP | $152.82M | 13.57 | 10.36M | 0% | +$0 | 40.4 | |
| Patient Square Capital Lp | $105.94M | 9.4 | 7.18M | New | +$105.94M | 45.11 | |
| BlackRock | $55.28M | 4.91 | 3.75M | +6.18% | +$3.22M | <0.01 | |
| The Vanguard Group | $42.59M | 3.78 | 2.89M | +1.52% | +$639,441.99 | <0.01 | |
| Kynam Capital Management Lp | $33.16M | 2.94 | 2.25M | -16.68% | -$6.64M | 0.42 |